Understanding Tysabri and PML Risk: What California Patients Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Understanding Tysabri and PML Risk

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection, linked to the JC virus, can occur in patients on this medication. Building on decades of pharmacovigilance research, this page outlines current understanding of PML symptoms, risk stratification, and what ongoing monitoring involves.

Find Out If You Qualify for Compensation →

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn’s disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies three established risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be considered when initiating and continuing therapy. The clinical presentation of PML is variable but typically includes progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual changes, and speech difficulties. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. Because PML can mimic multiple sclerosis relapses, clinicians must maintain a high index of suspicion. The boxed warning instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking lymphocyte adhesion and migration across the blood-brain barrier, Tysabri reduces immune surveillance in the central nervous system. This allows latent JC virus, which is present in a majority of the population, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal death. The risk is highest in patients with anti-JCV antibodies, as these indicate prior exposure to the virus. Longer treatment duration increases cumulative immunosuppression, and prior use of other immunosuppressants compounds the risk. Adequacy of warnings is a central issue in legal claims. The boxed warning explicitly states that Tysabri increases PML risk and that the drug is available only through the TOUCH Prescribing Program, a restricted distribution system designed to ensure patients are informed of risks and monitored (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers adequately communicated the magnitude of risk, the specific risk factors, and the need for vigilant monitoring. For patients who developed PML, the timeline between exposure and documented harm is critical. PML can occur after months to years of treatment, with the highest risk after two years. The boxed warning notes that duration of therapy is a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adverse event reports from the FDA FAERS database list fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder among the most frequently reported events for Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these are not specific to PML, they underscore the range of neurological symptoms that may be reported.

Statute of Limitations for Tysabri Claims in California

For patients in California considering legal action, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered. In PML cases, the date of diagnosis is often the trigger. Because PML symptoms can be subtle and initially mistaken for multiple sclerosis progression, the discovery date may be later. Attorney considerations include evaluating whether the manufacturer provided adequate warnings, whether the prescriber followed TOUCH program requirements, and whether the patient was properly monitored. The timeline between Tysabri initiation and PML diagnosis is essential to establish causation and to determine if the statute of limitations has expired. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and a mandated monitoring program. Patients who develop PML face severe disability or death. Legal claims in California must be filed within the statutory period, typically two years from discovery of the injury. Evidence of inadequate warnings or failure to monitor may support a claim. The mechanistic link between Tysabri and PML is grounded in its immunosuppressive effect on the central nervous system, and the clinical presentation requires prompt diagnosis and drug discontinuation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in California?

In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For PML cases, the date of diagnosis often triggers the clock. Because PML symptoms can be subtle and initially mistaken for multiple sclerosis progression, the discovery date may be later. It is crucial to consult an attorney promptly to evaluate your specific timeline.

What are the risk factors for developing PML while taking Tysabri?

The prescribing information for Tysabri identifies three established risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.